CapForce IBD Breakout Opportunities ETF (BOUT)

NYSE · US Equities - US Style · USA

Are the companies inside BOUT undervalued?

The companies inside BOUT trade 14% above what we estimate they are worth. We could give a verdict on 78% of the fund's weight: 27 holdings as reported to the SEC at 31 Jul 2026.

Where the money is: 4% in companies in the buy zone, 18% about fairly valued, 55% overvalued, 22% without a verdict.

What does BOUT hold?

The ten largest holdings, with our verdict on each:

How much does the BOUT fee cost?

Its expense ratio is 0.80% a year: on $10,000 held flat that is $800 over 10 years and $1,600 over 20.

Browse

Other US Equities - US Style ETFs